ITFG2

Across TCGA pan-cancer cohorts, ITFG2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ITFG2 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ITFG2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ITFG2 expression acts as an unfavorable survival marker, although some lineages such as HNSC and PDAC show a favorable association.

LUAD, UCEC, and HNSC are the cancer types where ITFG2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.905	0.974	.013	5	view →
UCEC	OS	Median	II,III,IV	0.653	1.000	.020	4	view →
HNSC	OS	Tertile	All	0.815	0.587	.013	4	view →
PDAC	OS	Tertile	IV	0.943	0.231	.024	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ITFG2–LUAD (OS)

Open the LUAD breakdown →